Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac’s Sales of H1N1 Vaccine Now Top 20 Million Doses

publication date: Jan 13, 2010
Sinovac Biotech (北京科兴生物制品有限公司) has received the fifth order for its H1N1 vaccine, Panflu.1™, from China's Ministry of Industry and Information Technology. The latest order is for 8.57 million doses of the vaccine, bringing total Sinovac sales to 20 million doses. Sinovac must deliver 2.3 million doses by March 15, 2010, and the balance will be stockpiled in Sinovac’s warehouse. More details...

Stock Symbol: (NSDQ: SVA)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here